P Manders

Summary

Affiliation: Radboud University Nijmegen Medical Centre
Country: The Netherlands

Publications

  1. ncbi Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer
    Peggy Manders
    Department of Chemical Endocrinology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Cancer Res 64:659-64. 2004
  2. ncbi Vascular endothelial growth factor levels do not predict efficacy of systemic adjuvant treatment as assessed in 1127 breast cancer patients
    P Manders
    Department of Chemical Endocrinology 530, University Medical Centre Nijmegen, NL 6500 HB Nijmegen, The Netherlands
    Int J Oncol 25:511-7. 2004
  3. ncbi The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer
    Peggy Manders
    Department of Chemical Endocrinology, 530, University Medical Centre Nijmegen, P O Box 9101, NL 6500 HB Nijmegen, The Netherlands
    Thromb Haemost 91:514-21. 2004
  4. ncbi Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients
    Peggy Manders
    Department of Chemical Endocrinology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Clin Cancer Res 9:6363-70. 2003
  5. ncbi The prognostic value of the mitotic activity index in patients with primary breast cancer who were not treated with adjuvant systemic therapy
    P Manders
    Department of Medical Oncology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Breast Cancer Res Treat 77:77-84. 2003
  6. pmc Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome
    P N Span
    Department of Chemical Endocrinology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Br J Cancer 89:271-6. 2003
  7. pmc The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy
    P Manders
    Department of Medical Oncology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Br J Cancer 87:772-8. 2002
  8. doi In primary breast cancer the mitotic activity yields similar prognostic information as the histological grade: a study with long-term follow-up
    P Bult
    Department of Pathology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Breast Cancer Res Treat 122:77-86. 2010
  9. ncbi Lifestyle Risk Factors for Breast Cancer in BRCA1/2-Mutation Carriers Around Childbearing Age
    A van Erkelens
    Department of Human Genetics 836, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands
    J Genet Couns . 2016
  10. doi Young age and a positive family history of colorectal cancer are complementary selection criteria for the identification of Lynch syndrome
    P Manders
    Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Eur J Cancer 47:1407-13. 2011

Detail Information

Publications25

  1. ncbi Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer
    Peggy Manders
    Department of Chemical Endocrinology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Cancer Res 64:659-64. 2004
    ..The results of this study imply that the expression of uPA:PAI-1 complex independently predicts the efficacy of adjuvant chemotherapy in patients with primary breast cancer...
  2. ncbi Vascular endothelial growth factor levels do not predict efficacy of systemic adjuvant treatment as assessed in 1127 breast cancer patients
    P Manders
    Department of Chemical Endocrinology 530, University Medical Centre Nijmegen, NL 6500 HB Nijmegen, The Netherlands
    Int J Oncol 25:511-7. 2004
    ..We conclude that tumor levels of VEGF do not predict the efficacy of adjuvant endocrine therapy or chemotherapy in patients with primary breast cancer...
  3. ncbi The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer
    Peggy Manders
    Department of Chemical Endocrinology, 530, University Medical Centre Nijmegen, P O Box 9101, NL 6500 HB Nijmegen, The Netherlands
    Thromb Haemost 91:514-21. 2004
    ..Further studies are warranted to explain this underlying resistance to endocrine therapy when uPA:PAI-I levels are high...
  4. ncbi Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients
    Peggy Manders
    Department of Chemical Endocrinology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Clin Cancer Res 9:6363-70. 2003
    ..We investigated the association between VEGF levels in tumor tissue and the effect of radiotherapy for relapse-free survival (RFS) and overall survival (OS) in node-negative breast cancer...
  5. ncbi The prognostic value of the mitotic activity index in patients with primary breast cancer who were not treated with adjuvant systemic therapy
    P Manders
    Department of Medical Oncology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Breast Cancer Res Treat 77:77-84. 2003
    ....
  6. pmc Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome
    P N Span
    Department of Chemical Endocrinology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Br J Cancer 89:271-6. 2003
    ..Thus, the determination of CA9 levels could aid in the selection of patients who will not benefit from adjuvant therapy, and whose prognosis will more likely improve with other treatment modalities...
  7. pmc The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy
    P Manders
    Department of Medical Oncology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Br J Cancer 87:772-8. 2002
    ..This implies that vascular endothelial growth factor is related with the natural course of breast cancer progression...
  8. doi In primary breast cancer the mitotic activity yields similar prognostic information as the histological grade: a study with long-term follow-up
    P Bult
    Department of Pathology, Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Breast Cancer Res Treat 122:77-86. 2010
    ..As histological grade is a well established and widely used prognosticator we do not have arguments to replace the histological grade by the mitotic indices MAI or M/V-index...
  9. ncbi Lifestyle Risk Factors for Breast Cancer in BRCA1/2-Mutation Carriers Around Childbearing Age
    A van Erkelens
    Department of Human Genetics 836, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands
    J Genet Couns . 2016
    ..Physical inactivity was 4-5 times more likely in carriers with children. Overweight was not associated with having children. Carriers with children are a subgroup that may specifically benefit from lifestyle support to reduce BC risk...
  10. doi Young age and a positive family history of colorectal cancer are complementary selection criteria for the identification of Lynch syndrome
    P Manders
    Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Eur J Cancer 47:1407-13. 2011
    ..Families from patients selected by individual criteria more often harbour extracolonic Lynch syndrome associated malignancies...
  11. ncbi Educational-support groups for BRCA mutation carriers satisfy need for information but do not affect emotional distress
    K M Landsbergen
    Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Genet Couns 21:423-37. 2010
    ..The aim of this study is to evaluate educational-support groups, which are offered to facilitate mutual support between BRCA mutation carriers and to provide adequate information...
  12. ncbi Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients
    Maxime Look
    Erasmus MC, Josephine Nefkens Institute, Rm Be 428, P O Box 1738, 3000 DR Rotterdam, The Netherlands
    Thromb Haemost 90:538-48. 2003
    ..We conclude that uPA and PAI-1 are ready to be used in the clinic to help classify breast cancer patients into high and low risk groups...
  13. ncbi Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer
    Paul N Span
    Department of Chemical Endocrinology, University Medical Center Nijmegen, Nijmegen, The Netherlands
    Oncogene 21:8506-9. 2002
    ..This seems - at least in part - to be attributable to its role in transcriptional regulation of factors involved in angiogenesis (VEGF), and extracellular matrix remodeling (PAI-1)...
  14. ncbi High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer
    Paul N Span
    Department of Chemical Endocrinology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Breast Cancer Res Treat 98:223-30. 2006
    ..024, log-rank). Thus, high levels of survivin are mainly related with a poor response to endocrine therapy, but a good response to chemotherapy. This phenomenon might be related to the different functions of survivin...
  15. ncbi Survivin is an independent prognostic marker for risk stratification of breast cancer patients
    Paul N Span
    Departments of Chemical Endocrinology, Clinical Chemistry, Medical Oncology, University Medical Center Nijmegen, Nijmegen, The Netherlands
    Clin Chem 50:1986-93. 2004
    ..Results in previous qualitative studies of the association of the apoptosis inhibitor survivin with prognosis of breast cancer patients have been contradictory...
  16. ncbi Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma
    Peggy Manders
    Department of Chemical Endocrinology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Cancer 101:486-94. 2004
    ..Both uPA and PAI-1 are established prognostic factors for patients with breast carcinoma. In the current study, the authors investigated whether the complex of uPA with PAI-1 is also associated with the natural course of this malignancy...
  17. ncbi Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma
    Paul N Span
    Department of Chemical Endocrinology, University Medical Center Nijmegen, The Netherlands
    Cancer 97:2710-5. 2003
    ..Its expression is essential for normal vasculogenesis. Down-regulation of RECK has been implicated in tumor angiogenesis and progression...
  18. ncbi Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success
    Paul N Span
    Department of Chemical Endocrinology, University Medical Center Nijmegen, Nijmegen, The Netherlands
    J Pathol 202:395-402. 2004
    ..0003). Thus, high tumour levels of the matrix metalloproteinases inhibitor and pro-apoptotic factor TIMP-3 are associated with successful tamoxifen treatment of patients with breast cancer...
  19. ncbi E1AF expression levels are not associated with prognosis in human breast cancer
    Paul N Span
    Department of Chemical Endocrinology, University Medical Center Nijmegen, Nijmegen, The Netherlands
    Breast Cancer Res Treat 79:129-31. 2003
    ..Furthermore, no association of E1AF levels with HER2/neu mRNA levels, hormone receptor status, histological grade, tumor size, or lymph node involvement was found...
  20. ncbi Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time
    Paul N Span
    Department of Chemical Endocrinology, University Medical Center Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    J Clin Oncol 22:691-8. 2004
    ..The tumor mRNA expression levels of mammaglobin, a novel breast-specific and breast cancer-associated marker, were correlated with disease outcome in 280 patients with primary breast cancer...
  21. ncbi Molecular beacon reverse transcription-PCR of human chorionic gonadotropin-beta-3, -5, and -8 mRNAs has prognostic value in breast cancer
    Paul N Span
    Department of Chemical Endocrinology, University Medical Center Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    Clin Chem 49:1074-80. 2003
    ..The beta-subunit of human chorionic gonadotropin (hCG) is encoded by four genes, of which expression of the hCGbeta-3, -5, and -8 genes could have prognostic value in breast cancer...
  22. ncbi Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer
    Paul N Span
    Department of Chemical Endocrinology, University Medical Center Nijmegen, Nijmegen, The Netherlands
    Oncogene 22:4898-904. 2003
    ..Differences in literature on the presumed prognostic value of cyclin-E may be due to differences in treatment. Assessment of cyclin-E levels can aid in improving adjuvant treatment selection...
  23. ncbi Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma
    Peggy Manders
    Department of Chemical Endocrinology, University Medical Center Nijmegen, Nijmegen, The Netherlands
    Cancer 98:2125-32. 2003
    ..In the current study, the authors investigated whether there was an association between VEGF levels in tumor tissues and response rates to first-line, systemic therapy in patients with advanced breast carcinoma...
  24. ncbi Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
    Maxime P Look
    Department of Medical Oncology, University Hospital Rotterdam, The Netherlands
    J Natl Cancer Inst 94:116-28. 2002
    ....
  25. pmc Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
    Antonis C Antoniou
    Cancer Research UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK
    Am J Hum Genet 82:937-48. 2008
    ....